ArticleAntimicrobial agents and chemotherapy2015
Fungal β-1,3-glucan increases ofloxacin tolerance of Escherichia coli in a polymicrobial E. coli/Candida albicans biofilm.
Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 97 citations in OpenAlex.
- Bacterial-fungal interactions: connections and consequences.Essays in biochemistry · 2026Review
- Artemisinin effects on Gastrointestinal tissues in Candida albicans-infected mice: histological and functional evaluation.Journal of molecular histology · 2025Article
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- The Human Mycobiome: Composition, Immune Interactions, and Impact on Disease.International journal of molecular sciences · 2025Review
- Dectin-1 stimulating β-glucans inhibit Chlamydia infections both in vitro and in vivo.Pathogens and disease · 2025Article
- Impact of overlapping fungal infection on the occurrence and prognosis of carbapenem-resistant gram-negative bacilli infection.Frontiers in cellular and infection microbiology · 2025Observational
- Intestinal biofilms: pathophysiological relevance, host defense, and therapeutic opportunities.Clinical microbiology reviews · 2024Review
- The gut microbiota composition is linked to subsequent occurrence of ventilator-associated pneumonia in critically ill patients.Microbiology spectrum · 2023Article
- Pseudomonas aeruginosa increases the susceptibility of Candida albicans to amphotericin B in dual-species biofilms.The Journal of antimicrobial chemotherapy · 2023Article
- Bridging gut microbiota composition with extended-spectrum beta-lactamase Enterobacteriales faecal carriage in critically ill patients (microbe cohort study).Annals of intensive care · 2023Article
- Antifungal drug-resistance mechanisms in Candida biofilms.Current opinion in microbiology · 2023Review
- Article
- Transcriptional profilingMicrobiology (Reading, England) · 2023Article
- Candida albicans Promotes the Antimicrobial Tolerance of Escherichia coli in a Cross-Kingdom Dual-Species BiofilmMicroorganisms · 2022Article
- Enhanced Antibiotic Tolerance of anMicroorganisms · 2022Article
- Hydroalcoholic Leaf Extract ofAntibiotics (Basel, Switzerland) · 2022Article
- Polymicrobial Biofilm Dynamics of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- An intestinalVeterinary world · 2022Article
- Pharmacodynamics of Moxifloxacin, Meropenem, Caspofungin, and Their Combinations againstAntimicrobial agents and chemotherapy · 2022Article
- Inhibition of polymicrobial biofilm formation by saw palmetto oil, lauric acid and myristic acid.Microbial biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past, biofilm-related research has focused mainly on axenic biofilms. However, in nature, biofilms are often composed of multiple species, and the resulting polymicrobial interactions influence industrially and clinically relevant outcomes such as performance and drug resistance. In this study, we show that Escherichia coli does not affect Candida albicans tolerance to amphotericin or caspofungin in an E. coli/C. albicans biofilm. In contrast, ofloxacin tolerance of E. coli is significantly increased in a polymicrobial E. coli/C. albicans biofilm compared to its tolerance in an axenic E. coli biofilm. The increased ofloxacin tolerance of E. coli is mainly biofilm specific, as ofloxacin tolerance of E. coli is less pronounced in polymicrobial E. coli/C. albicans planktonic cultures. Moreover, we found that ofloxacin tolerance of E. coli decreased significantly when E. coli/C. albicans biofilms were treated with matrix-degrading enzymes such as the β-1,3-glucan-degrading enzyme lyticase. In line with a role for β-1,3-glucan in mediating ofloxacin tolerance of E. coli in a biofilm, we found that ofloxacin tolerance of E. coli increased even more in E. coli/C. albicans biofilms consisting of a high-β-1,3-glucan-producing C. albicans mutant. In addition, exogenous addition of laminarin, a polysaccharide composed mainly of poly-β-1,3-glucan, to an E. coli biofilm also resulted in increased ofloxacin tolerance. All these data indicate that β-1,3-glucan from C. albicans increases ofloxacin tolerance of E. coli in an E. coli/C. albicans biofilm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.